GEN Exclusives

More »

GEN News Highlights

More »
Sep 27, 2006

Peter MacCallum Cancer Centre and Affymetrix Initiate Research Collaboration

  • Affymetrix entered into a five-year collaboration with the Peter MacCallum Cancer Centre in Melbourne, Australia, to analyze genomic information across large patient samples. Under terms of the agreement, Peter Mac researchers will use Affymetrix’ GeneChip® microarray technology for translational research projects, beginning with studies on ovarian cancer and carcinoma of unknown primaries.

    The Affymetrix technology will enable them to more rapidly discover RNA and DNA patterns that can better classify, manage, and treat complex diseases.

    “We are keen to help our collaborators across Australia gain access to Affymetrix technology, as we continue to develop as a major center for cancer genomics and genetics,” says David Bowtell, Ph.D., director of research at the Peter MacCallum Cancer Centre. “We also see the program providing opportunities to interact with other centers worldwide that are involved in translational research.”



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?